NCT00076336 - Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | Biotech Hunter

Enrollment

232

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2009

Conditions

HepatitisHepatitis B, ChronicCirrhosis

Interventions

DRUG

Telbivudine

600mg/day oral tablet for 104 weeks

DRUG

Lamivudine

100mg/day oral tablet for 104 weeks

DRUG

Placebo

Telbivudine matching placebo or lamivudine matching placebo tablet.

Trial Locations (28)

Unknown

Phoenix

Los Angeles

Denver

Indianapolis

Rochester

New York

Houston

Madison

Heidelburg

Winnipeg

Hong Kong

Villejuif

Hanover

Novartis, New Delhi

Tel Aviv

Novartis, Riga

Novartis, Kuala Lumpur

Auckland

Novartis, Krakow

Novartis, Moscow

Singapore

Seoul

Barcelona

Taipei

Bangkok

Novartis, Istanbul

London

Novartis, Hanoi